Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Remnant uptake as a postoperative oncologic quality indicator.

Schneider DF, Ojomo KA, Chen H, Sippel RS.

Thyroid. 2013 Oct;23(10):1269-76. doi: 10.1089/thy.2012.0451.

2.

Effects of low-dose and high-dose postoperative radioiodine therapy on the clinical outcome in patients with small differentiated thyroid cancer having microscopic extrathyroidal extension.

Han JM, Kim WG, Kim TY, Jeon MJ, Ryu JS, Song DE, Hong SJ, Shong YK, Kim WB.

Thyroid. 2014 May;24(5):820-5. doi: 10.1089/thy.2013.0362.

3.

Therapeutic implications of diffuse hepatic uptake following I-131 therapy for differentiated thyroid cancer.

Ferris HA, Williams G, Parker JA, Garber JR.

Endocr Pract. 2013 Mar-Apr;19(2):263-7. doi: 10.4158/EP12077.OR.

PMID:
23529347
4.

Combined use of radioiodine therapy and radiofrequency ablation in treating postsurgical thyroid remnant of differentiated thyroid carcinoma.

Long B, Li L, Yao L, Chen S, Yi H, Ye X, Xu D, Wu P.

J Cancer Res Ther. 2015 Nov;11 Suppl:C244-7. doi: 10.4103/0973-1482.170530.

5.

Radioactive iodine remnant uptake after completion thyroidectomy: not such a complete cancer operation.

Oltmann SC, Schneider DF, Leverson G, Sivashanmugam T, Chen H, Sippel RS.

Ann Surg Oncol. 2014 Apr;21(4):1379-83. doi: 10.1245/s10434-013-3450-3.

6.

Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.

Molinaro E, Giani C, Agate L, Biagini A, Pieruzzi L, Bianchi F, Brozzi F, Ceccarelli C, Viola D, Piaggi P, Vitti P, Pacini F, Elisei R.

J Clin Endocrinol Metab. 2013 Jul;98(7):2693-700. doi: 10.1210/jc.2012-4137.

PMID:
23626005
7.

[Size of postoperative thyroid remnant as oncological quality parameter].

Dralle H.

Chirurg. 2014 Mar;85(3):256. doi: 10.1007/s00104-014-2706-1. German. No abstract available.

PMID:
24496752
8.
9.

Correlation between cervical uptake and results of postsurgical radioiodine ablation in patients with thyroid carcinoma.

Rosário PW, Maia FF, Cardoso LD, Barroso A, Rezende L, Padrão EL, Purisch S.

Clin Nucl Med. 2004 Jun;29(6):358-61.

PMID:
15166882
10.
11.

Thyroid ablation with 1.1 GBq (30 mCi) iodine-131 in patients with papillary thyroid carcinoma at intermediate risk for recurrence.

Rosário PW, Calsolari MR.

Thyroid. 2014 May;24(5):826-31. doi: 10.1089/thy.2013.0479.

PMID:
24283207
12.

Efficacy of low and high 131I doses for thyroid remnant ablation in patients with differentiated thyroid carcinoma based on post-operative cervical uptake.

Rosário PW, Reis JS, Barroso AL, Rezende LL, Padrão EL, Fagundes TA.

Nucl Med Commun. 2004 Nov;25(11):1077-81.

PMID:
15577584
13.

Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates.

Karam M, Gianoukakis A, Feustel PJ, Cheema A, Postal ES, Cooper JA.

Nucl Med Commun. 2003 May;24(5):489-95. Erratum in: Nucl Med Commun. 2003 Jul;24(7):843.

PMID:
12717064
14.

Low but measurable stimulated serum thyroglobulin levels <2 µg/L frequently predict incomplete response in differentiated thyroid cancer patients.

Aldawish M, Jha N, McEwan AJ, Severin D, Ghosh S, Morrish DW.

Endocr Res. 2014;39(4):157-63. doi: 10.3109/07435800.2013.865211.

PMID:
24460082
15.
16.

Measuring the extent of total thyroidectomy for differentiated thyroid carcinoma using radioactive iodine imaging: relationship with serum thyroglobulin and clinical outcomes.

Holsinger FC, Ramaswamy U, Cabanillas ME, Lang J, Lin HY, Busaidy NL, Grubbs E, Rahim S, Sturgis EM, Lee JE, Weber RS, Clayman GL, Rohren EM.

JAMA Otolaryngol Head Neck Surg. 2014 May;140(5):410-5. doi: 10.1001/jamaoto.2014.264.

PMID:
24700275
17.

Impact of pregnancy on prognosis of differentiated thyroid cancer: clinical and molecular features.

Messuti I, Corvisieri S, Bardesono F, Rapa I, Giorcelli J, Pellerito R, Volante M, Orlandi F.

Eur J Endocrinol. 2014 Apr 10;170(5):659-66. doi: 10.1530/EJE-13-0903.

18.

Thyroid remnant ablation following administration of a diagnostic dose of iodine-131 under thyrogen stimulation.

Wu D, Fink-Bennett D, Campbell J.

Thyroid. 2014 May;24(5):924-5. doi: 10.1089/thy.2013.0454. No abstract available.

PMID:
24483713
19.

Comparison of 800 and 3700 MBq iodine-131 for the postoperative ablation of thyroid remnant in patients with low-risk differentiated thyroid cancer.

Caglar M, Bozkurt FM, Akca CK, Vargol SE, Bayraktar M, Ugur O, Karaağaoğlu E.

Nucl Med Commun. 2012 Mar;33(3):268-74. doi: 10.1097/MNM.0b013e32834ec5d6.

PMID:
22205241
Items per page

Supplemental Content

Support Center